NCT03166085View on ClinicalTrials.gov

PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 23, 2017

Primary Completion Date

December 14, 2021

Study Completion Date

December 14, 2021

Conditions
Metastatic Breast Cancer
Interventions
DRUG

PU-H71

PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle

DRUG

Nab-paclitaxel

nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Samus Therapeutics, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03166085 - PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter